NCT04588922 2026-03-16
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Sellas Life Sciences Group
Phase 1/2 Recruiting
Sellas Life Sciences Group
Gustave Roussy, Cancer Campus, Grand Paris
American Regent, Inc.
University of California, Davis
IGM Biosciences, Inc.